Tirzepatide's Cardiovascular Win, H5N1 Surveillance, and a Record Dengue Season

Cardiology, infectious disease, and cognitive health converge in today's roundup: a GLP-1/GIP drug reaches a cardiovascular endpoint, H5N1 surveillance is tightened on US dairy farms, dengue closes a near-record year in the Americas, Mediterranean diet data offer a cognitive dividend, WHO accelerates mpox vaccine delivery in central Africa, and an mRNA tuberculosis vaccine enters phase 2 in South Africa.

Thursday, 29 October: Tirzepatide Cuts Major Cardiovascular Events in Obesity Trial

Eli Lilly's tirzepatide (Zepbound) significantly reduced the rate of major adverse cardiovascular events (MACE) in adults with obesity but without type 2 diabetes in the SURMOUNT-CVOT trial, published in the New England Journal of Medicine. The randomised, placebo-controlled trial enrolled approximately 15,000 adults with a body mass index ≥ 27, established cardiovascular disease, and no diabetes diagnosis at enrolment. After a median follow-up of 3.4 years, tirzepatide reduced the composite MACE endpoint — cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke — by 20% compared with placebo (hazard ratio 0.80; 95% CI 0.72–0.89; p < 0.001).

The result closely mirrors the 2023 SELECT trial, in which semaglutide (Wegovy, Novo Nordisk) reduced MACE by 20% in a similarly defined population. Together, the two trials establish a cardiovascular benefit for the GLP-1 drug class in obesity that appears to extend beyond what weight loss alone would predict — pointing to anti-inflammatory and plaque-stabilising mechanisms still being characterised. Tirzepatide is a dual GIP/GLP-1 agonist, binding both glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors; its dual action produces greater average weight reduction than GLP-1 monotherapy, and the SURMOUNT-CVOT result raises the prospect that this may translate to a modestly larger cardiovascular benefit over time.

The European Society of Cardiology released a guidance statement alongside the publication, recommending discussion of GLP-1/GIP agonists as part of comprehensive cardiovascular risk reduction in eligible patients with obesity and established disease. For patients and clinicians, the trial provides cardiovascular grounds — beyond obesity management alone — for considering this drug class in those at highest cardiac risk. Confirmatory analysis of longer follow-up data and pre-specified subgroups is expected in the coming year.

Thursday, 29 October: CDC Updates H5N1 Farm Worker Guidance as Dairy Infections Persist

The US Centers for Disease Control and Prevention issued updated occupational exposure guidance for farm workers in contact with H5N1-infected dairy cattle, as the virus continues circulating in herds across more than a dozen US states entering the autumn season. The updated framework strengthens respiratory protection requirements for workers involved in milking operations and animal health checks, and expands the threshold for antiviral prophylaxis with oseltamivir to include workers with any unprotected exposure to infected animals, regardless of symptom onset.

As of late October 2026, the CDC has confirmed sporadic human cases among farm workers, all without evidence of human-to-human transmission. The virus' sustained presence in cattle — now entering a third season — combined with the onset of cold weather that prolongs pathogen viability on surfaces, prompted the guidance revision. The WHO's global risk assessment remains low for the general public but elevated for occupationally exposed individuals.

For the Mediterranean region, the situation carries indirect relevance. H5N1 has been detected in migratory bird populations traversing Cyprus and Greece on Atlantic-Mediterranean flyways; veterinary and wild-bird surveillance in the region should be read against the backdrop of what sustained dairy-herd transmission in North America is revealing about the virus's evolutionary trajectory and its capacity to adapt to mammalian hosts.

Thursday, 29 October: Dengue Reaches Near-Record 13 Million Cases in the Americas

The Pan American Health Organization's end-of-season bulletin reports nearly 13 million confirmed and probable dengue cases in the Americas through 26 October 2026, approaching the 12.5 million registered in 2024 and exceeding every prior year in the epidemiological record save one. Brazil accounts for more than 80% of the hemisphere's burden, but significant outbreaks have also occurred in Argentina, Colombia, Paraguay, and several Caribbean island territories.

The sustained severity of successive dengue seasons reflects converging pressures: the Aedes aegypti mosquito's range has expanded northward and to higher altitudes as average temperatures rise; the large 2024 outbreak reshaped population immunity in ways that left many communities newly susceptible to circulating serotypes; and urbanisation in lower-income areas continues to provide standing water and close-quarter conditions that favour transmission. The WHO notes that dengue has now been locally transmitted in parts of Europe — including Madeira, the Canary Islands, and sporadic cases on the Iberian mainland and southern France — and that Mediterranean health systems should include dengue in differential diagnoses for febrile travellers returning from endemic zones, including those returning from the Caribbean.

Thursday, 29 October: Mediterranean Diet Linked to Slower Cognitive Decline in Large Cohort

A longitudinal study published in The Lancet Neurology followed 9,800 adults aged 55–80 across six Mediterranean countries — Spain, Italy, Greece, Cyprus, Turkey, and Croatia — over eight years, using validated food-frequency questionnaires and standardised neuropsychological testing at two-year intervals. High adherence to a Mediterranean diet — rich in olive oil, legumes, fish, vegetables, and whole grains, with low red-meat and processed-food consumption — was associated with a 23% slower rate of composite cognitive decline compared with low adherence, after adjusting for age, sex, education, physical activity, and cardiovascular risk factors.

The association was strongest for executive function and verbal memory, the cognitive domains that tend to decline earliest in Alzheimer's disease. Effect sizes were similar across the largest country subsamples — Spain, Italy, and Greece — suggesting the finding is not specific to a single national food culture. The study had sufficient statistical power to distinguish between overall diet quality and total caloric intake; caloric restriction alone did not account for the benefit.

This is observational evidence and cannot establish causation. Randomised controlled trials of dietary interventions in dementia prevention have produced mixed results, in part because such trials are difficult to blind and to sustain over the required time horizon. But the consistency of this Mediterranean-specific finding in an independent, well-powered cohort adds meaningful weight to public-health guidance encouraging Mediterranean eating patterns, particularly in Cyprus and the broader Levantine region where adherence to traditional diets has been declining among younger cohorts.

Thursday, 29 October: WHO Ships 500,000 Mpox Vaccine Doses to DRC as Clade Ib Spreads

The World Health Organization and Gavi confirmed the dispatch of 500,000 doses of the MVA-BN vaccine (Jynneos/Imvanex) to the Democratic Republic of Congo, as the mpox clade Ib outbreak — declared a Public Health Emergency of International Concern in August 2024 — continues to expand geographically. WHO surveillance reports that new provinces in the DRC recorded their first clade Ib cases in October 2026, and the virus has been confirmed in Burundi and eastern Rwanda, a geographic extension beyond the outbreak's original epicentre in South Kivu.

Clade Ib has demonstrated more efficient person-to-person transmission than the clade IIb variant responsible for the 2022–23 global outbreak, primarily through sexual contact but also through close household transmission among children. Vaccine roll-out in the DRC has been constrained by cold-chain logistics, community trust, and competing health priorities. The October delivery is part of a Gavi-funded scale-up aiming to reach 2 million doses in the region by early 2027. The ECDC continues to monitor for importations into Europe, which remain sporadic and linked to travel from outbreak-affected areas.

Thursday, 29 October: Phase 2 mRNA Tuberculosis Vaccine Trial Opens in South Africa

BioNTech and the Wellcome Trust announced the opening of enrolment for a phase 2 efficacy trial of BNT164b2, an mRNA-based tuberculosis vaccine candidate, at research sites in Cape Town and Johannesburg. The trial will enrol approximately 3,000 HIV-negative adults aged 18–50 who previously received BCG vaccination and will measure incidence of pulmonary tuberculosis over 24 months as its primary endpoint.

Tuberculosis kills approximately 1.25 million people annually, making it the world's leading infectious-disease killer. The BCG vaccine, now over a century old, provides reasonable protection against severe childhood tuberculosis but is poorly protective against pulmonary disease in adults. The mRNA approach encodes antigens from mycobacterial proteins associated with active disease progression, aiming to prime a T-cell response better suited to clearing established infection. Phase 1 data, published in The Lancet Infectious Diseases in early 2026, demonstrated an acceptable safety profile and evidence of immunogenicity. If phase 2 results confirm partial protection, this would represent the most significant tuberculosis vaccine advance in more than a century.

The content above is journalistic reporting and does not constitute medical advice. Readers should consult a qualified clinician before making any change to their treatment, medication, or health management.